Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°£³» ´ã°ü¾ÏÁ¾¿¡¼­ÀÇ p53, Rb, bcl-2 ´Ü¹é ¹ßÇö°ú Ki-67 Ç¥ÁöÁö¼ö¿ÍÀÇ »ó°ü°ü°è Expression of p53, Rb, bcl-2 Proteins and Ki-67 Labeling Index in Intrahepatic Cholangiocarcinoma

´ëÇѺ´¸®ÇÐȸÁö 2003³â 37±Ç 3È£ p.186 ~ 192
±¸¹ÌÁø, ±èÈ«Áø, ÃÖÁØÇõ, À±¼º¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
±¸¹ÌÁø ( Gu Mi-Jin ) 
¼º»ïº´¿ø Çغκ´¸®°ú

±èÈ«Áø ( Kim Hong-Jin ) 
¿µ³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÃÖÁØÇõ ( Choi Joon-Hyuk ) 
¿µ³²´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
À±¼º¼ö ( Yun Sung-Soo ) 
¿µ³²´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Background: The development and progression of a tumor can be determined by a complex multistep process involving the activation of oncogenes and the inactivation of tumor suppressor genes. The purpose of this study is to investigate the expression of p53, Rb, bcl-2 protein and Ki-67 labeling index in the intrahepatic cholangiocarcinoma.

Methods: We analyzed 36 cases of intrahepatic cholangiocarcinoma obtained by surgical resection. Expression of p53, Rb, bcl-2 proteins and Ki-67 labeling index were evaluated by immunohistochemical study.

Results: Expression of p53 protein was detected in 61.1% (22/36) of cholangiocarcinoma. Rb protein loss and overexpression were observed 27.8% (7/36) and 72.2% (29/36) of cholangiocarcinoma. But bcl-2 protein was not expressed. No significant correlation was found between p53, Rb and bcl-2 protein expression and age, sex, gross type, histologic grade, vascular invasion and lymph node metastases. The Ki-67 labeling index was significantly higher in p53 positive group and Rb overexpression group than in p53 negative group (p<0.01) and Rb loss group (p<0.05). There was a positive correlation between p53 protein and Rb protein expressions, but a negative correlation between Rb protein and bcl-2 protein expressions.

Conclusion: The overexpression of p53 protein and Rb protein may be closely associated with cholangiocarcinogenesis, while bcl-2 has a less crucial role in cholangiocarcinogenesis.

Å°¿öµå

Liver neoplasms;Cholangiocarcinoma;p53 protein;Rb protein;bcl-2 protein;Ki-67

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS